CTOs on the Move

AVEO Oncology

www.aveooncology.com

 
AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering and developing targeted therapies designed to provide substantial impact in patients` lives with clear unmet medical needs. AVEO`s proprietary Human Response PlatformTM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

AVEO Oncology raised $35M on 08/10/2020
AVEO Oncology raised $48M on 03/24/2021

Similar Companies

MGC Diagnostics Corporation

MGC Diagnostics Corporation is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wellstart International Inc

Wellstart International Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Delaware Health Information Network

In 2007 the Delaware Health Information Network (DHIN) became the first live, statewide health information network in the nation. DHIN currently serves: - 100% of Delaware’s acute care hospitals - 100% of Delaware’s long term care and skilled nursing facilities - Approaching 100% of medical providers who have enrolled and are participating in DHIN More than 14,000,000 clinical results and reports are posted on DHIN each year – and the total patient records in the system now exceed 2,100,000, featuring patient records from all 50 states. In the six years that DHIN has been active, the system has proven its reliability and worth to hospitals, medical professionals and patients throughout Delaware. DHIN securely delivers fast and accurate patient information from hospitals, laboratories, and radiology facilities directly to doctors’ offices. DHIN makes it possible to deliver higher quality medical care more quickly, and at a lower cost, using a federated data model for medical records, aggregating those records and eliminating the manual transmittal of medical data. Frequent audits confirm that the system is secure and that data is used properly. The Delaware Health Information Network (DHIN) was enacted by the Delaware General Assembly in 1997 as a public-private partnership for the benefit of all citizens of Delaware to advance the creation of a statewide health information network and to address Delaware`s needs for timely, reliable and relevant health care information.

Assembly Biosciences

Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.

ControlRad Systems

ControlRad is a privately-held medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from fluoroscopically guided interventional procedures (FGIP) for patients and healthcare professionals.